课题基金 / 基金详情

Characterization of Erbb Receptors in Nanoparticles

Characterization of Erbb Receptors in Nanoparticles
纳米颗粒中 Erbb 受体的表征
批准号:
8187225
负责人:
Matthew Adrian Coleman
金额:
$31.85万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-07-07 至 2016-05-31

项目摘要

项目成果

Matthew Adrian Coleman的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):超过30%的蛋白质与细胞膜结合,这使得它们难以以可溶性和活性形式分离。我们建议实施最近开发的纳米脂蛋白颗粒(NLP),以允许以活性形式分离膜结合蛋白。NLP是当载脂蛋白和磷脂群体在可溶解活性膜结合蛋白的水性环境中自组装成脂质双层时形成的盘状纳米颗粒。特别是,我们将集中在酪氨酸激酶受体,介导许多癌症的传播和几个化疗药物的目标的表征。在细胞环境外研究这些受体的能力将使结构和机制研究能够更好地理解致癌作用和其他疾病。鉴于膜相关蛋白占药物靶点的大多数,因此开发新技术以获得这类重要的蛋白质是很重要的。本研究的主要目的是开发普遍适用的方法来生产、分离和表征人I型酪氨酸激酶受体ErbB1、ErbB2、ErbB3和ErbB4。已知表皮生长因子受体家族在细胞信号传导和癌发生中是重要的。这些蛋白质是具有挑战性的研究,因为它们的不溶性和倾向于聚集在水溶液中。该提案的重点是开发一种新的生物技术应用,从而形成能够溶解这些和其他膜结合蛋白的NLP。NLP在粒径单分散性和溶解度方面比目前使用的模型膜具有明显的优势。该提案将通过在NLP中合成ErbB受体的同源和异源二聚体,表征其结构和功能并进行文库筛选来进行,以鉴定可作为先导化合物进一步开发为药物的新型高亲和力肽和小分子。 公共卫生相关性:我们建议将纳米技术应用于研究膜结合蛋白质的问题,这些蛋白质由于水溶性差和蛋白质变性而难以研究。表皮生长因子(ErbB)家族的膜结合受体蛋白是我们的模型系统,用于开发一种无细胞的蛋白质表达技术,能够生产几乎任何膜蛋白的水溶性功能形式,易于研究。我们将合成含ErbB的纳米颗粒,并对其结构,功能以及与肽和小分子库的结合进行表征。
英文摘要
DESCRIPTION (provided by applicant): Over 30% of proteins are bound to cell membranes, which makes them difficult to isolate in a soluble and active form. We propose to implement recently developed nanolipoprotein particles (NLPs) to allow the separation of membrane-bound proteins in an active form. NLPs are discoidal nanoparticles formed when an apolipoprotein and a population of phospholipids self-assemble into a lipid bilayer in an aqueous environment that can solubilize active membrane-bound proteins. In particular, we will focus on characterization of tyrosine kinase receptors, which mediate the spread of many cancers and are targets of several chemotherapeutics. The ability to study these receptors outside the cell environment will enable structural and mechanistic studies for improved understanding of carcinogenesis and other diseases. Given that membrane-associated proteins account for the majority of drug targets, it is important to develop novel technologies to gain access to this important class of proteins. This main goal is to develop generally applicable methods to produce, isolate and characterize the human type I tyrosine kinase receptors ErbB1, ErbB2, ErbB3 and ErbB4. The epidermal growth factor families of receptors are known to be important in cell signaling and carcinogenesis. These proteins are challenging to study because of their insolubility and tendency to aggregate in aqueous solutions. This proposal is focused on developing a new biotechnology application leading to formation of NLPs capable of solubilizing these and other membrane-bound proteins. The NLPs present a distinct advantage over currently used model membranes in terms of particle size monodispersity and solubility. This proposal will be carried out by synthesizing homo- and heterodimers of ErbB receptors in NLPs, characterizing them for structure and function and performing library screening in order to identify novel high-affinity peptides and small molecules that can serve as lead compounds for further development as drugs. PUBLIC HEALTH RELEVANCE: We propose to apply nanotechnology to the problem of studying membrane-bound proteins, which are difficult to study owing to poor aqueous solubility and protein denaturation. The epidermal growth factor (ErbB) family of membrane-bound receptor proteins is our model system for developing a cell-free protein expression technology capable of producing virtually any membrane protein in a water-soluble functional form that is easy to study. We will synthesize ErbB-containing nanoparticles and characterize them for structure, function and for binding to peptide and small molecule libraries.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Project 1. Nanolipoprotein-supported multi-subunit vaccine for Chlamydia trachomatis
Induction of cross C. trachomatis serovar protection utilizing a polyvalent nanoparticle vaccine.
Cooperative Research Center for NanoScaffold-Based Chlamydia trachomatis Vaccines - Admin Core
Induction of cross C. trachomatis serovar protection utilizing a polyvalent nanoparticle vaccine.
海外基金